Astrana Health, Inc. (NASDAQ:ASTH) Given Average Rating of "Moderate Buy" by Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $53.29.

A number of equities analysts recently commented on ASTH shares. Barclays assumed coverage on Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 target price for the company. Robert W. Baird lowered their price target on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Stifel Nicolaus lowered their price target on Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Bank of America decreased their price objective on Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, Truist Financial cut their price target on Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th.

Astrana Health Stock Performance

Shares of Astrana Health stock opened at $27.06 on Friday. Astrana Health has a one year low of $23.12 and a one year high of $63.20. The company has a market cap of $1.52 billion, a price-to-earnings ratio of 20.82, a PEG ratio of 1.37 and a beta of 1.00. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The business's 50 day moving average price is $30.82 and its 200 day moving average price is $35.62.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.09). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $620.39 million during the quarter, compared to analysts' expectations of $628.11 million. During the same quarter in the prior year, the firm earned $0.31 EPS. Astrana Health's revenue for the quarter was up 53.4% compared to the same quarter last year. On average, research analysts predict that Astrana Health will post 1.15 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Astrana Health in the fourth quarter valued at $40,000. Quarry LP boosted its stake in Astrana Health by 35.5% in the 4th quarter. Quarry LP now owns 1,799 shares of the company's stock worth $57,000 after buying an additional 471 shares during the last quarter. Covestor Ltd raised its holdings in shares of Astrana Health by 777.6% in the 1st quarter. Covestor Ltd now owns 2,001 shares of the company's stock worth $62,000 after purchasing an additional 1,773 shares during the period. KBC Group NV raised its holdings in shares of Astrana Health by 108.4% in the 4th quarter. KBC Group NV now owns 2,530 shares of the company's stock worth $80,000 after purchasing an additional 1,316 shares during the period. Finally, US Bancorp DE raised its holdings in shares of Astrana Health by 3,880.0% during the 4th quarter. US Bancorp DE now owns 4,776 shares of the company's stock valued at $151,000 after buying an additional 4,656 shares during the period. Hedge funds and other institutional investors own 52.77% of the company's stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.